がん治療薬とワクチンの開発を手がけるバイオ企業Curevacは、バイオ企業向けの投資会社Dieviniから2,760万ユーロの資金を受ける。これにより2012年までの研究開発資金を確保。前立腺がんと肺がんの臨床試験のほか、感染症用ワクチンの開発に充てる。Curevacは2017～19年をめどに同社初の医薬品を市場投入する考えで、2012年からは製薬会社などと提携し、コストのかさむ最終段階の臨床試験や販売事業を委ねる方針だ。11日付『フランクフルター・アルゲマイネ』紙がCurevacの創業者であるイングマール・ヘル社長への取材をもとに報じた。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
